Background:  The epidermal growth factor (EGF) family constitutes a group of class B, G protein-coupled receptors, which includes CD97 and EMR2. EMR2 is a member of the EGF-TM7 receptor subfamily. EGF-TM7 receptors are a family of class B, seven-span transmembrane (TM7) receptors predominantly expressed by cells of the immune system. Within the TM7 superfamily, the molecular structure and ligand-binding properties of EGF-TM7 receptors are unique. Derived from the processing of a single polypeptide, they are expressed at the cell surface as heterodimers consisting of a large extracellular region associated with a TM7 moiety. Through a variable number of N-terminal EGF-like domains, EGF-TM7 receptors interact with cellular ligands such as CD55 and chondroitin sulfate. EMR2 is a heptahelical molecule predominantly expressed on cells of the immune system such as leukocytes. EMR2 is proteo-lytically cleaved into two separate subunits: a seven-transmembrane subunit, and an extracellular Alpha subunit.

Description: Rabbit polyclonal to EMR2

Immunogen: KLH conjugated synthetic peptide derived from EMR2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 90 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.